Der Internist

, Volume 47, Issue 3, pp 233–241

Renale Anämie — eine wichtige Folgeerkrankung der Niereninsuffizienz

  • C. Mayer
  • H. Achenbach
  • M. Stumvoll
  • G. M. Fiedler
Schwerpunkt: Folgeerkrankungen
  • 157 Downloads

Zusammenfassung

Die renale Anämie als eine der wichtigsten Folgeerkrankungen der chronischen Niereninsuffizienz hat einen hohen Stellenwert in der Behandlung nierenkranker Patienten. Hauptursache der renalen Anämie ist eine inadäquat niedrige Produktion an endogenem Erythropoietin. Ein häufig begleitender absoluter und funktioneller Eisenmangel muss im Rahmen der Diagnostik und Therapie besonders berücksichtigt werden. Die Substitution von rekombinantem humanem Erythropoietin (R-HuEPO) ist die effektivste Behandlungsmaßnahme. Ziel ist ein stabiler Hämoglobinwert >11 g/dl. Der häufig zusätzlich bestehende Eisenmangel sollte adäquat und leitliniengerecht ausgeglichen werden. Durch eine konsequente und frühzeitige Behandlung können Morbidität, Mortalität und Lebensqualität nachhaltig verbessert werden.

Schlüsselwörter

Renale Anämie Chronische Niereninsuffizienz Erythropoietin Eisenmangel 

Renal anemia — an important secondary disease in renal insufficiency

Abstract

Anemia is as a frequent complication in patients with chronic kidney disease, which gains in importance in the treatment of patients with renal disease. The main cause of renal anemia is the inadequately low production of endogenous erythropoietin. Often the patients develop an additional absolute or functional iron deficiency, which complicates the diagnostic and therapeutic procedures. Substitution of recombinant human erythropoietin (r-HuEPO) is the most effective therapy. The goal is a stable haemoglobin level >11 g/dl. An often additional existing iron deficiency should be balanced adequately according to the guidelines. With consequent and early treatment morbidity, mortality, and quality of life can be effectively improved.

Keywords

Renal anemia Chronic kidney disease Erythropoietin Iron deficiency 

Literatur

  1. 1.
    Hsu CY, McCulloch CE, Curhan GC (2002) Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13: 504–510CrossRefPubMedGoogle Scholar
  2. 2.
    Ritz E, Haxsen V (2005) Diabetic nephropathy and anaemia. Eur J Clin Invest 35 [Suppl 3]: 66–74CrossRefPubMedGoogle Scholar
  3. 3.
    Caro J, Brown S, Miller O, Murray T, Erslev AJ (1979) Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 93: 449–458PubMedGoogle Scholar
  4. 4.
    Stevens LA, Levin A (2003) Anaemia, cardiovascular disease and kidney disease: integrating new knowledge in 2002. Curr Opin Nephrol Hypertens 12: 133–138CrossRefPubMedGoogle Scholar
  5. 5.
    Eckardt KU, Kurtz A (2005) Regulation of erythropoietin production. Eur J Clin Invest 35 [Suppl 3]: 13–19CrossRefGoogle Scholar
  6. 6.
    Koury MJ, Bondurant MC (1990) Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 248: 378–381PubMedGoogle Scholar
  7. 7.
    Maxwell PH, Ferguson DJ, Nicholls LG, Johnson MH, Ratcliffe PJ (1997) The interstitial response to renal injury: fibroblast-like cells show phenotypic changes and have reduced potential for erythropoietin gene expression. Kidney Int 52: 715–724PubMedGoogle Scholar
  8. 8.
    Eckardt KU, Mollmann M, Neumann R et al. (1989) Erythropoietin in polycystic kidneys. J Clin Invest 84: 1160–1166PubMedGoogle Scholar
  9. 9.
    Stenvinkel P (2001) The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant 16 [Suppl 7]: 36–40Google Scholar
  10. 10.
    Deicher R, Horl WH (2004) Hepcidin: a molecular link between inflammation and anaemia. Nephrol Dial Transplant 19: 521–524CrossRefPubMedGoogle Scholar
  11. 11.
    Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352: 1011–1023CrossRefPubMedGoogle Scholar
  12. 12.
    Cole J, Ertoy D, Lin H et al. (2000) Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice. J Clin Invest 106: 1391–1398PubMedGoogle Scholar
  13. 13.
    Freudenthaler SM, Lucht I, Schenk T, Brink M, Gleiter CH (2000) Dose-dependent effect of angiotensin II on human erythropoietin production. Pflugers Arch 439: 838–844CrossRefPubMedGoogle Scholar
  14. 14.
    European Best Practice Guidelines Working Group (2004) Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Section IV. Failure to respond to treatment. Nephrol Dial Transplant 19 [Suppl 2]: ii32–ii36CrossRefGoogle Scholar
  15. 15.
    Foley RN, Parfrey PS, Sarnak MJ (1998) Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9: S16–23CrossRefPubMedGoogle Scholar
  16. 16.
    Locatelli F, Pisoni RL, Combe C et al. (2004) Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19: 121–132CrossRefPubMedGoogle Scholar
  17. 17.
    Levin A (2002) The relationship of haemoglobin level and survival: direct or indirect effects? Nephrol Dial Transplant 17 [Suppl 5]: 8–13CrossRefGoogle Scholar
  18. 18.
    Eckardt KU (2005) Managing a fateful alliance: anaemia and cardiovascular outcomes. Nephrol Dial Transplant 20 [Suppl 6]: vi16–20CrossRefPubMedGoogle Scholar
  19. 19.
    Rao M, Pereira BJ (2005) Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. Kidney Int 68: 1432–1438CrossRefPubMedGoogle Scholar
  20. 20.
    Kazmi W, Kausz A, Khan S, Abichandani R, Ruthazer R, Obrador G, Pereira B (2001) Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 38: 803–812PubMedGoogle Scholar
  21. 21.
    Thomas L, Thomas C, Heimpel H (2005) Neue Parameter zur Diagnostik von Eisenmangelzuständen. Dtsch Ärztebl 102: A580–586Google Scholar
  22. 22.
    Brugnara C (2000) Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit Rev Clin Lab Sci 37: 93–130CrossRefPubMedGoogle Scholar
  23. 23.
    Thomas C, Thomas L (2002) Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 48: 1066–1076PubMedGoogle Scholar
  24. 24.
    Fishbane S, Kalantar-Zadeh K, Nissenson AR (2004) Serum ferritin in chronic kidney disease: reconsidering the upper limit for iron treatment. Semin Dial 17: 336–341CrossRefPubMedGoogle Scholar
  25. 25.
    Brugnara C (2002) A hematologic „gold standard“ for iron-deficient states? Clin Chem 48: 981–982PubMedGoogle Scholar
  26. 26.
    Thomas C (2005) Transferrin-Sättigung (TfS) Thomas, Labor und Diagnose, 6. Auflage, Frankfurt am Main, pp 409–411Google Scholar
  27. 27.
    Thomas C, Thomas L (2005) Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 11: 14–23CrossRefPubMedGoogle Scholar
  28. 28.
    Jacobs C, Frei D, Perkins A (2005) Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant 20: iii1–iii2CrossRefGoogle Scholar
  29. 29.
    Hörl W, Vanrenterghem Y, Canaud B, Mann J, Teatini U, Wanner C, Wikström B (2005) Optimal Treatment of Renal Anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin. Nephrol Dial Transplant 20: iii25–iii32CrossRefPubMedGoogle Scholar
  30. 30.
    Khan S, Kazmi W, Abichandani R, Tighiouart H, Pereira B, Kausz A (2002) Health care utilization among patients with chronic kidney disease. Kidney Int 62: 229–236CrossRefPubMedGoogle Scholar
  31. 31.
    Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O (1997) Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77: 176–185PubMedGoogle Scholar
  32. 32.
    McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ (2000) Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 15: 1425–1430CrossRefPubMedGoogle Scholar
  33. 33.
    Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA (1998) Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 339: 578–583CrossRefPubMedGoogle Scholar
  34. 34.
    Besarab A, Bolton WK, Browne JK et al. (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584–590CrossRefPubMedGoogle Scholar
  35. 35.
    Macdougall IC (1995) Poor response to erythropoietin: practical guidelines on investigation and management. Nephrol Dial Transplant 10: 607–614PubMedGoogle Scholar
  36. 36.
    Kooistra MP, Niemantsverdriet EC, van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJ (1998) Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant 13: 82–88CrossRefGoogle Scholar
  37. 37.
    Besarab A, Amin N, Ahsan M et al. (2000) Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11: 530–538PubMedGoogle Scholar
  38. 38.
    (2001) IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 37: S182–238Google Scholar
  39. 39.
    Rossert J, Casadevall N, Eckardt KU (2004) Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 15: 398–406CrossRefPubMedGoogle Scholar
  40. 40.
    Silverberg DS, Wexler D, Blum M, Iaina A (2003) The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clin Nephrol 60 [Suppl 1]: S93–102PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2006

Authors and Affiliations

  • C. Mayer
    • 1
    • 3
  • H. Achenbach
    • 1
  • M. Stumvoll
    • 1
  • G. M. Fiedler
    • 2
  1. 1.Abteilung für Endokrinologie, Diabetologie und NephrologieMedizinische Klinik und Poliklinik III, Universität Leipzig
  2. 2.Institut für Laboratoriumsmedizin, Klinische Chemie und Molekulare DiagnostikUniversität Leipzig
  3. 3.Abteilung für Endokrinologie, Diabetologie und NephrologieMedizinische Klinik und Poliklinik III, UniversitätsklinikumLeipzig

Personalised recommendations